How Will the Market React to Tarsus Pharmaceuticals Inc (TARS) Stock Getting a Bullish Rating

Overall market sentiment has been high on Tarsus Pharmaceuticals Inc (TARS) stock lately. TARS receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Tarsus Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on TARS!

See Full TARS Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With TARS Stock Today?

Tarsus Pharmaceuticals Inc (TARS) stock is trading at $18.74 as of 3:06 PM on Friday, Aug 12, a rise of $1.42, or 8.2% from the previous closing price of $17.32. The stock has traded between $16.41 and $19.66 so far today. Volume today is 60,206 compared to average volume of 78,824. To see InvestorsObserver's Sentiment Score for Tarsus Pharmaceuticals Inc click here.

More About Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites. Click Here to get the full Stock Report for Tarsus Pharmaceuticals Inc stock.